Objective: This randomized, double-blind, multicentre extension study compared the efficacy, tolerability, and safety of ziprasidone and risperidone for schizophrenia or schizoaffective disorder.
S chizophrenia is a chronic disease with a high risk for
relapse. An estimated 50% of patients with schizophrenia relapse within 1 year of their most recent episode, and 15% to 20% of those patients require hospitalization. Long-term antipsychotic therapy is critical to maintaining remission. Relapse rates may be as low as 26% for patients treated with an antipsychotic medication, compared with 69% for patients not receiving treatment. 1 Patients experiencing an initial episode of schizophrenia should receive treatment with antipsychotic agents for 1 to 2 years. After 2 or more episodes, patients should receive treatment for at least 5 years, and perhaps indefinitely. 2 As a class, atypical antipsychotic agents have a lower propensity to cause movement disorder adverse events than conventional antipsychotics, a major advantage in the long-term management of schizophrenia. [3] [4] [5] Some research suggests atypical antipsychotic agents may also provide greater amelioration of affective and cognitive symptoms and, thus, contribute to better long-term outcomes 2, 3 ; however, differences in their overall adverse event profiles often distinguish these agents from one another 6, 7 and are an important consideration in determining which drug may be optimal for an individual patient. It may also be possible that differences in efficacy that are not present in short-term trials may become evident in longer-term studies.
A body of evidence points to the long-term efficacy, safety, and tolerability of both ziprasidone and risperidone in the treatment of schizophrenia and schizoaffective disorder. Long-term clinical trials with ziprasidone include a 1-year, placebo-controlled, relapse-prevention study, 8 a 28-week study comparing the conventional antipsychotic agent haloperidol, 9 and a 6-month trial comparing the atypical antipsychotic olanzapine. 10 Ziprasidone was associated with a lower risk for hyperprolactinemia and movement disorders than was haloperidol 9 and carried a lower risk of weight gain and dyslipidemia than olanzapine. 10 Efficacy comparisons showed ziprasidone to be superior to haloperidol on the negative symptom subscale score of the PANSS and equivalent on all other outcome measures 9 ; in comparison with olanzapine, ziprasidone was equivalent on CGI-S. 10 Ziprasidone was significantly superior to placebo in preventing relapse during 1 year (P < 0.001 at 160 mg/day). 8 Long-term clinical trials of risperidone in patients with schizophrenia or schizoaffective disorder include a 28-week study, compared with olanzapine, 11 a 6-month study, compared with amisulpride, 12 and a 1-year relapse-prevention study, compared with haloperidol. 13 The 28-week and 6-month trials each showed similar efficacy for risperidone and the comparator drug, but amisulpride and olanzapine were both associated with less hyperprolactinemia. 11, 12 The year-long study was a double-blind, randomized, prospective trial in which clinically stable patients received risperidone (n = 177) or haloperidol (n = 188) for a median duration of 364 and 288 days, respectively. The study demonstrated the efficacy and safety of risperidone. Treatment with risperidone significantly (P < 0.001) reduced the risk of relapse and was associated with a small but statistically significant (P < 0.001) improvement in the PANSS total score, compared with the results for the haloperidol-treated patients. The risk of weight gain and hyperprolactinemia was greater with risperidone than with haloperidol, but the risk of EPS was less. 13 Ziprasidone has been compared with risperidone in a short-term, 8-week, double-blind study of efficacy and tolerability in patients with acute exacerbations of schizophrenia or schizoaffective disorder. 14 Both agents demonstrated equivalent efficacy in improving psychotic symptoms and overall psychopathology and both were well tolerated. More ziprasidone-treated patients discontinued the trial owing to lack of efficacy during the initial 14 days. This was attributed in part to inadequate dosing; protocol limited the rate of ziprasidone dosage titration over the first 2 weeks. Risperidone was associated with a higher incidence of abnormal movements, although this finding might have been caused by the higher dosage used. In the CATIE study, ziprasidone was similar to risperidone in efficacy and tolerability. 15 Discontinuation rates showed a nonstatistically significant trend in favour of risperidone: 74% of subjects treated with risperidone discontinued treatment within 18 months of initiation; 79% of ziprasidone-treated subjects discontinued treatment.
To assess the comparative long-term tolerability and efficacy of ziprasidone and risperidone in the treatment of schizophrenia and schizoaffective disorder, we conducted a 44-week, double-blind continuation study among patients who had responded to treatment during the 8-week trial. 14
Methods

Study Design and Subjects
This was a double-blind, parallel-group, multicentre, 44-week extension study, intended to assess the long-term safety, tolerability, and efficacy of flexible-dose regimens of ziprasidone and risperidone in patients recovering from an acute exacerbation of schizophrenia or schizoaffective disorder, as defined by DSM-III-R. The study was conducted in Australia, Canada, Ireland, Poland, New Zealand, and the United Kingdom between August 1, 1995, and December 19, 1997. Patients who had responded to treatment (in the opinion of the investigator) in the 8-week core study comparing ziprasidone and risperidone 14 were eligible to enter a 44-week extension involving the same double-blind treatment regimen. Eligible females must have been either of nonchildbearing potential or practicing successful contraception for at least 3 months prior to study entry. All subjects were outpatients and provided written informed consent.
The research received ethics approval from each site of this multicentre international study.
Treatments
Ziprasidone was flexibly dosed between 80 and 160 mg/day and risperidone between 6 and 10 mg/day during the continuation study. Doses of ziprasidone and risperidone could be adjusted weekly in 40-and 2-mg increments, respectively, according to the clinical judgment of the investigator and the occurrence of adverse events. Anticholinergic agents or propranolol, or both, were instituted or reinstituted as needed for control of EPS, while lorazepam and temazepam were permitted for agitation and insomnia. Neuroleptics, antidepressants, mood stabilizers, and other psychotropic drugs were prohibited.
Efficacy and Safety Assessments
Primary efficacy variables were the PANSS total score and the CGI-S score. Secondary efficacy variables included the PANSS negative subscore, the MADRS, and the GAF scale. All efficacy evaluations except the GAF were performed at baseline and at weeks 1, 3, 6, and 8 of the core study;
evaluations were repeated at weeks 16, 28, 40, and 52 of the extension study, or at premature discontinuation. GAF was performed at baseline, at week 8 of the core study, and at week 52 (or premature discontinuation) of the extension study. For all efficacy variables, change was measured from the core study baseline to the extension study end point.
Abnormal movements were assessed with the SARS for EPS, the BAS, and the AIMS. SARS and BAS evaluations were performed at baseline and at weeks 1, 3, 6, and 8 of the core study; they were repeated at weeks 16, 28, 40, and 52 of the extension study or at premature discontinuation. The AIMS evaluation was performed at baseline, at week 8 of the core study, and at week 52 of the extension study or at premature discontinuation. The MDB score was calculated to quantify the overall discomfort that patients experienced from movement disorders over the course of the study. The MDB score was included as a protocol-derived, a priori analysis and reflects the incidence, duration, and severity of movement disorders. The MDB score is calculated using the following formula:
where S is the movement disorder severity score, D is the duration of the adverse event in days, C is the concomitant medication factor (C = 1.5, if anticholinergics or beta-blockers were used for treating the movement disorder; C = 1, if no concomitant medication was used), and TTD is the total number of treatment days for the patient. 14 All observed or reported adverse events were recorded and assessed for severity, duration, and possible causal relation to the study drug. Laboratory assessments consisted of complete blood count, urinalysis, and blood chemistries. A physical examination, including weight measurement and a 12-lead electrocardiogram, was performed at screening, week 8, and study end point. Blood pressure and pulse were monitored at each visit.
Statistical Plan
Analyses of primary and secondary efficacy results were based on the ITT population, using the LOCF approach. Post hoc analysis was also performed using the completer population. ANCOVA was used for hypothesis testing (2-sided, significance set at P £ 0.05). Maintenance of response was assessed at each visit of the extension study. Responders were defined as those patients who had an improvement in PANSS total score of 20% or more from baseline to end point of the core study. Response was considered not to have been maintained if, at any visit during the extension study, PANSS total score increased by 20% or more and the CGI-S score was 3 or more (mild or greater). No adjustment for multiple comparisons was applied. Kaplan-Meier survival analysis was used to compare the time until discontinuation of response maintenance, using a log-rank test.
Results
Patient Demographics and Disposition
A total of 139 patients were entered into the extension study and received at least 1 dose of medication in a double-blind manner (ITT population). Treatment groups were similar in terms of history of psychiatric illness, severity of illness at baseline, and baseline demographics ( 53.3% (8/15) for ziprasidone and risperidone, respectivelyoccurred between week 8 (the start of the extension study) and week 28.
Efficacy Outcomes
Both ziprasidone and risperidone were associated with clinically relevant improvements as measured by scores for PANSS total, PANSS negative subscale, CGI-S, GAF, and MADRS (Table 3 ). In general, the magnitude of the mean changes from baseline in these efficacy variables increased at each visit up to week 8 (the last visit of the core study) and then remained stable for the 44-week extension treatment period. In the primary ITT analysis (LOCF), mean changes from core study baseline to end point of the 44-week extension study for the 2 treatment groups were not statistically significantly different for any efficacy variable (Table 3 ).
In the efficacy analysis of patients who completed the study, both ziprasidone and risperidone were associated with clinically relevant improvements as measured by scores for PANSS total, PANSS negative subscale, CGI-S, GAF, and MADRS ( Rates of maintenance of response were nearly identical in both groups at all time points. At study end point, 75% of subjects taking ziprasidone and 74% taking risperidone demonstrated maintenance of response. There was no significant difference in median time to discontinuation for the 2 groups (P = 0.86, log-rank test).
Tolerability and Safety Results
Treatment-emergent adverse events were experienced by 90.3% (56/62) of the ziprasidone-treated patients and by 92.2% (71/77) of the risperidone-treated patients. Adverse events judged by the investigators to be treatment-related were reported by 75.8% (47/62) of the ziprasidone group and by 72.7% (56/77) of the risperidone group. Most were mild or moderate in severity. Those occurring with greater frequency in the ziprasidone group included insomnia and vomiting, while risperidone was more frequently associated with somnolence, hypertonia, and increased salivation ( Table 5 ). Six subjects receiving ziprasidone and 5 receiving risperidone discontinued study participation for treatment-related adverse effects ( Table 2) .
Laboratory test abnormalities were found in 57.4% of patients (35/61) in the ziprasidone group and in 96.1% of patients (74/77) in the risperidone group. Median changes in prolactin levels were -8 ng/mL for the ziprasidone group and 26 ng/mL for the risperidone group. One ziprasidone-treated patient had an elevation of liver enzymes and was discontinued from the study.
Ziprasidone-treated patients gained less weight than those receiving risperidone. Fewer ziprasidone-treated patients had an increase in body weight of 7% or more ( formula for calculation of QTc) from the core trial baseline to the study end point was 4.6 ms in the ziprasidone group and -4.6 ms in the risperidone group. No subject in either group had a QTc interval of 450 ms or more; an increase in QTc interval of 50 ms or more occurred in 3 subjects in each group. No patient experienced a serious cardiac adverse event.
Discussion
This double-blind trial compared the long-term efficacy and tolerability of flexible-dose ziprasidone and risperidone. There have been relatively few long-term clinical trials directly comparing atypical antipsychotic agents, and only some of these have followed a double-blind design. 11, 12, 15, 16 Our results indicate that ziprasidone and risperidone are similarly effective in the continuation and maintenance treatment of patients with schizophrenia who have clinically responded to one of these agents for the treatment of an acute psychiatric exacerbation. Both the ziprasidone and risperidone groups showed clinically relevant improvement from baseline in PANSS and CGI-S scores at study end point. More risperidone-treated patients completed the study, but the difference in completion rates, compared with ziprasidone, was not statistically significant. Ziprasidone-treated patients who completed the study showed a greater improvement in depressive symptoms as measured by MADRS total score (P < 0.05) than risperidone-treated patients, based on a post hoc analysis. There was no difference between the agents in response-maintenance rates; such results are consistent with those observed in a 6-month trial comparing ziprasidone with olanzapine. 10 The rate of discontinuation from the study for all causes was 66% for the ziprasidone group and 58% for the risperidone group. These rates compare favourably with those from other long-term controlled studies of antipsychotic agents in the treatment of schizophrenia and schizoaffective disorder. In the CATIE study, the rate of discontinuation at 1 year for all causes was 79% for ziprasidone-treated patients and 74% for the risperidone group. 15 In another trial involving patients a Three ziprasidone-treated subjects and 2 risperidone-treated subjects were excluded from the all-subjects analysis because they had no core study postbaseline measurement for PANSS total, PANSS-derived variables, or CGI-S. The number of patients per test varied; therefore, n is given as a range. with new-onset schizophrenia, all-cause treatment discontinuation rates at 52 weeks were 68.4% for olanzapine, 70.9% for quetiapine, and 71.4% for risperidone. 17 A naturalistic, retrospective study using Medicaid data indicated that 90.4% of patients with schizophrenia discontinued atypical antipsychotic medication within 1 year and that discontinuation rates were similar for all atypical antipsychotics including ziprasidone and risperidone. 18 Insufficient clinical response caused a slightly higher proportion of ziprasidone-treated patients to discontinue the study (25.8%, compared with 19.5% for risperidone). The higher rate of ziprasidone discontinuations may have been dose-related; that is, the mean dosage of ziprasidone in this study (114 mg/day) was lower than current clinical practice and what is presently regarded as optimal treatment. 19 A recent PET study of patients with schizophrenia who underwent PET scanning after 3 weeks of ziprasidone administration demonstrated that a dosage of ziprasidone of 120 mg/day is associated with about 60% D 2 -receptor occupancy, the level at which antipsychotic agents begin to exhibit clinical response. 20 In phase 3 clinical trials of ziprasidone in the treatment of patients with schizophrenia and schizoaffective disorder (duration 4 to 8 weeks), the largest effect sizes were seen at dosages of 120 to 160 mg/day. 19, 21, 22 Finally, a naturalistic, retrospective study in patients with schizophrenia showed that ziprasidone discontinuation risk closely correlated with dosage. Patients taking dosages of less than 120 mg/day were much more likely to discontinue treatment than those receiving 120 to 160 mg/day (P = 0.001). 23, 24 The mean daily dosage of risperidone (8 mg) was the recommended dosage at the time the study was conducted, but is higher than current clinical guidelines. 25, 26 Studies of risperidone use in actual practice found a mean dosage of 7.1 mg/day of risperidone to be effective (in hospitalized patients). 27 The risperidone US package insert at the time of this study (and currently) noted that a 4-week placebocontrolled risperidone study in acute schizophrenia comparing fixed dosages of 4 and 8 mg/day found that, for multiple measures of psychopathology, "results were generally stronger for the 8 mg than for the 4 mg dose group." 28 Both ziprasidone and risperidone were generally well tolerated in our study. There was no difference in the overall incidence and severity of adverse events (Table 5 ). Ziprasidone was associated with a greater reduction in EPS and need for concomitant anticholinergic treatment. The greater degree of discomfort from movement disorders reported among the risperidone patients might have been related, at least in part, to the dosing regimen. Dosages of risperidone of 8 mg/day or more have been associated with higher rates of EPS than have dosages of 6 mg/day or more. 25, 29, 30 Modest weight gain was more common among the risperidone patients. Ziprasidone, in contrast, had a neutral effect on weight. Hyperprolactinemia, which has been associated with menstrual irregularities, galactorrhea, and sexual dysfunction, was also more common in risperidone-treated patients. 31 Changes in prolactin levels are thought to be largely independent of dose.
These efficacy and safety results are consistent with data from other long-term trials comparing ziprasidone with placebo, 8 haloperidol, 9 or olanzapine. 10 In a 6-month continuation study in patients with acute exacerbations of schizophrenia or schizoaffective disorder who responded to treatment in a 6-week randomized trial, ziprasidone (mean dosage, 135.2 mg/day) and olanzapine (mean dosage 12.6 mg/day) showed comparable efficacy, as demonstrated by the CGI-S and PANSS scores. 10 Tolerability was generally similar for both medications.
Results from this study are also consistent with those from long-term trials comparing risperidone to haloperidol, 13 amisulpride, 12 or olanzapine. 11 In these studies, risperidone demonstrated antipsychotic efficacy and overall tolerability similar to that of the other atypical agents, and it was superior to haloperidol. The improvements we documented by PANSS and CGI-S scores and other efficacy outcomes were comparable or superior to those achieved with risperidone in other medium-length or long-term comparative trials with haloperidol or other atypical antipsychotic agents. 5, 32 Although this was a rigorously conducted randomized, blinded study, there were several limitations that must be considered. The mean dosage of ziprasidone was lower than the dosage associated with maximum efficacy, whereas the mean risperidone dosage was higher than that currently thought associated with optimal treatment. This may have obscured clinically relevant differences between the 2 agents. As well, the number of subjects might not have been large enough to document statistically significant differences in various outcome measures.
Conclusions
This long-term, randomized controlled trial demonstrated similar efficacy for ziprasidone and risperidone in patients with schizophrenia or schizoaffective disorder. There were no statistically significant differences in primary and secondary efficacy measures in the analysis of the all-patients population. Differences between treatment groups for tolerability included less adverse effect on weight, EPS measures, and prolactin with ziprasidone. A slightly lower proportion of risperidone-treated patients discontinued the study for treatment-related reasons. These findings add to the limited amount of published data directly addressing the long-term comparative efficacy and tolerability of atypical antipsychotic medications. Future research using more optimal dosing of both agents and evaluating more specific outcome measures, such as cognitive or occupational function, could help to identify clinically relevant distinctions between these atypical antipsychotic medications.
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